David Rich

David Rich has an extensive work experience in the pharmaceutical and biotechnology industry. David has held various leadership positions throughout their career. From 2023 to present, they have been working as Vice President, Program Leader, Oncology at ITM Isotope Technologies Munich SE. Prior to that, from 2022 to 2023, they were Vice President, Asset Lead at Oak Hill Bio. From 2015 to 2022, they worked at Ipsen, where they held multiple roles including Vice President, Global Asset Lead, Rare Diseases, R&D and Vice President, Global Development, Rare Diseases, Global R&D. David also worked at INC Research as Senior Director, Clinical Operations and Head of European Site Management from 2013 to 2015. Before that, they held the position of Associate Director Medical Affairs, Oncology, Europe at Astellas Pharma Europe from 2012 to 2013. From 2004 to 2012, they held various roles at Novartis, including Medical Affairs Manager - Oncology and Medical Development Manager Oncology. David started their career in 2001 as a Scientific Adviser - Immunology at Wyeth.

David Rich's education history includes a Bachelor of Science BSc Hons (Sandwich) degree in Biomedical Science from the University of Wolverhampton, which they obtained between 1991 and 1995. David then pursued a Master of Philosophy (MPhil) degree in Immunology at the University of Southampton from 1995 to 1998. In 2017, they completed an Oncology Recertification course in Cancer Medicine & Haematology at Harvard Medical School. Currently, they are enrolled in the Strategic Leadership Programme at Saïd Business School, University of Oxford, with an expected completion year of 2022.